Skip to main content
SpringerLink
Log in

GlaxoSmithKline's Alli [orlistat] and Lily/Amylin's Byetta [exenatide] are making impacts in the obesity drug market,

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources.GlaxoSmithKline's Alli Impacting Both Physicians' Prescribing Habits for Obesity Drugs and Managed Care's Reimbursement Policies for Xenical. Media Release: 4 Dec 2007. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

GlaxoSmithKline's Alli [orlistat] and Lily/Amylin's Byetta [exenatide] are making impacts in the obesity drug market,. Pharmacoecon. Outcomes News 543, 11 (2007). https://doi.org/10.2165/00151234-200705430-00033

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705430-00033

Keywords

Search

Navigation